BioCryst Pharmaceuticals (NASDAQ:BCRX) is a biotechnology company focused on developing oral treatments for rare diseases. The company has made significant strides in the pharmaceutical industry, particularly with its drug ORLADEYO® (berotralstat), which targets hereditary angioedema (HAE). BioCryst competes with other biotech firms in the rare disease treatment space, striving to offer innovative solutions.

On December 15, 2025, H.C. Wainwright maintained its "Buy" rating for BioCryst, with the stock priced at $7.64. The firm also raised its price target from $30 to $32, indicating confidence in the company's future performance. This optimism is supported by recent developments, such as the FDA's expanded approval of ORLADEYO for children aged 2 to under 12 years.

The FDA's approval of ORLADEYO in an oral pellet formulation is a significant milestone for BioCryst. This child-friendly method of administration is crucial, as approximately 40% of children with HAE experience their first attack by age 5. The drug has shown early and sustained reductions in monthly attack rates, offering a promising solution for managing this life-threatening condition.

BioCryst's stock is currently priced at $7.60, reflecting a slight increase of 0.33% or $0.025. The stock has fluctuated between $7.57 and $7.92 today, with a 52-week high of $11.31 and a low of $6. The company's market capitalization stands at approximately $1.6 billion, with a trading volume of 1,923,583 shares today.

The expanded approval of ORLADEYO is expected to enhance BioCryst's market presence and impact. By extending the reach of their treatment to a younger demographic, the company is well-positioned to capture a larger share of the HAE market. This development aligns with H.C. Wainwright's positive outlook and increased price target for NASDAQ:BCRX.